Letter to the Editor
Split Viewer
Blood Res 2018; 53(2):
Published online June 25, 2018
https://doi.org/10.5045/br.2018.53.2.172
© The Korean Society of Hematology
Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
1Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
2The Prosserman Family Neurology Clinic, Toronto General Hospital, University Health Network, Toronto, Canada.
Correspondence to : Simon Kavanagh. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre 610 University Ave., Toronto, ON, M5G 2M9, Canada. simon.kavanagh@uhn.ca
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
PDF
Standard view
Export citation
Share Article
Letter to the Editor
Blood Res 2018; 53(2): 172-174
Published online June 25, 2018 https://doi.org/10.5045/br.2018.53.2.172
Copyright © The Korean Society of Hematology.
Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
Simon Kavanagh1*, Vera Bril2, and Jeffrey H Lipton1
1Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
2The Prosserman Family Neurology Clinic, Toronto General Hospital, University Health Network, Toronto, Canada.
Correspondence to:Simon Kavanagh. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre 610 University Ave., Toronto, ON, M5G 2M9, Canada. simon.kavanagh@uhn.ca
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Previous Article
